US20110155157A1 - Cigarette filter containing rosemary extract and a method of reducing dna damage caused by harmful agents in cigarette smoke by use of said filter - Google Patents
Cigarette filter containing rosemary extract and a method of reducing dna damage caused by harmful agents in cigarette smoke by use of said filter Download PDFInfo
- Publication number
- US20110155157A1 US20110155157A1 US12/515,040 US51504009A US2011155157A1 US 20110155157 A1 US20110155157 A1 US 20110155157A1 US 51504009 A US51504009 A US 51504009A US 2011155157 A1 US2011155157 A1 US 2011155157A1
- Authority
- US
- United States
- Prior art keywords
- bpde
- filter
- cigarette
- cigarette smoke
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 235000019504 cigarettes Nutrition 0.000 title claims abstract description 78
- 239000000779 smoke Substances 0.000 title claims abstract description 66
- 238000000034 method Methods 0.000 title claims abstract description 26
- 235000020748 rosemary extract Nutrition 0.000 title abstract description 14
- 229940092258 rosemary extract Drugs 0.000 title abstract description 11
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 title abstract description 11
- 239000003795 chemical substances by application Substances 0.000 title abstract description 6
- 230000006378 damage Effects 0.000 title description 3
- 210000004072 lung Anatomy 0.000 claims abstract description 13
- RXGCXARXEYBFKU-UHFFFAOYSA-N benzo[a]pyrene-1,2-diol Chemical compound C1=C2C=CC=CC2=C2C=CC3=C(O)C(O)=CC4=CC=C1C2=C43 RXGCXARXEYBFKU-UHFFFAOYSA-N 0.000 claims abstract description 7
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims description 16
- -1 polyphenol compounds Chemical class 0.000 claims description 15
- 241001529742 Rosmarinus Species 0.000 claims description 9
- 230000000391 smoking effect Effects 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 7
- XUSYGBPHQBWGAD-PJSUUKDQSA-N Carnosol Chemical compound CC([C@@H]1C2)(C)CCC[C@@]11C(=O)O[C@@H]2C2=C1C(O)=C(O)C(C(C)C)=C2 XUSYGBPHQBWGAD-PJSUUKDQSA-N 0.000 claims description 6
- MMFRMKXYTWBMOM-UHFFFAOYSA-N Carnosol Natural products CCc1cc2C3CC4C(C)(C)CCCC4(C(=O)O3)c2c(O)c1O MMFRMKXYTWBMOM-UHFFFAOYSA-N 0.000 claims description 6
- 235000004654 carnosol Nutrition 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 5
- 241000207923 Lamiaceae Species 0.000 claims description 3
- 235000013824 polyphenols Nutrition 0.000 claims 6
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 claims 4
- 241000196324 Embryophyta Species 0.000 claims 2
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 claims 2
- 230000001476 alcoholic effect Effects 0.000 claims 2
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 claims 2
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- CEEMRWKKNNEQDT-UHFFFAOYSA-N Rosmanol Natural products CC(C)c1cc2C(OC(=O)C)C3OC(=O)C4(CCCC(C)(C)C34)c2c(OC(=O)C)c1OC(=O)C CEEMRWKKNNEQDT-UHFFFAOYSA-N 0.000 claims 1
- 238000000605 extraction Methods 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 239000003094 microcapsule Substances 0.000 claims 1
- 150000008442 polyphenolic compounds Chemical class 0.000 claims 1
- LCAZOMIGFDQMNC-FORWCCJISA-N rosmanol Chemical compound C1CCC(C)(C)[C@@H]2[C@H]3[C@@H](O)C(C=C(C(=C4O)O)C(C)C)=C4[C@]21C(=O)O3 LCAZOMIGFDQMNC-FORWCCJISA-N 0.000 claims 1
- FMMWHPNWAFZXNH-UHFFFAOYSA-N Benz[a]pyrene Chemical class C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 FMMWHPNWAFZXNH-UHFFFAOYSA-N 0.000 abstract description 116
- 230000005778 DNA damage Effects 0.000 abstract description 8
- 231100000277 DNA damage Toxicity 0.000 abstract description 8
- 210000005260 human cell Anatomy 0.000 abstract description 7
- 230000009467 reduction Effects 0.000 abstract description 5
- TXVHTIQJNYSSKO-UHFFFAOYSA-N BeP Natural products C1=CC=C2C3=CC=CC=C3C3=CC=CC4=CC=C1C2=C34 TXVHTIQJNYSSKO-UHFFFAOYSA-N 0.000 description 54
- 210000004027 cell Anatomy 0.000 description 52
- 230000015572 biosynthetic process Effects 0.000 description 41
- 108020004414 DNA Proteins 0.000 description 36
- 230000000694 effects Effects 0.000 description 25
- 150000003254 radicals Chemical class 0.000 description 16
- 239000003183 carcinogenic agent Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 231100000357 carcinogen Toxicity 0.000 description 14
- 101150051438 CYP gene Proteins 0.000 description 13
- 230000000711 cancerogenic effect Effects 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 239000012071 phase Substances 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 11
- 230000001419 dependent effect Effects 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 10
- 230000004913 activation Effects 0.000 description 10
- 230000007423 decrease Effects 0.000 description 10
- 238000010790 dilution Methods 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 201000005202 lung cancer Diseases 0.000 description 10
- 208000020816 lung neoplasm Diseases 0.000 description 10
- 239000001301 oxygen Substances 0.000 description 10
- 229910052760 oxygen Inorganic materials 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- DQEPMTIXHXSFOR-UHFFFAOYSA-N benzo[a]pyrene diol epoxide I Chemical compound C1=C2C(C3OC3C(C3O)O)=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 DQEPMTIXHXSFOR-UHFFFAOYSA-N 0.000 description 8
- DQEPMTIXHXSFOR-WCIQWLHISA-N (+)-anti-bpde Chemical compound C1=C2C([C@H]3O[C@H]3[C@H]([C@@H]3O)O)=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 DQEPMTIXHXSFOR-WCIQWLHISA-N 0.000 description 7
- 241000208125 Nicotiana Species 0.000 description 7
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 230000000977 initiatory effect Effects 0.000 description 7
- 230000004060 metabolic process Effects 0.000 description 7
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 6
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 6
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 6
- 231100000504 carcinogenesis Toxicity 0.000 description 6
- 231100000315 carcinogenic Toxicity 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 230000002503 metabolic effect Effects 0.000 description 6
- 102000016938 Catalase Human genes 0.000 description 5
- 108010053835 Catalase Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 150000002009 diols Chemical class 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 108010067770 Endopeptidase K Proteins 0.000 description 4
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 4
- DJOWTWWHMWQATC-KYHIUUMWSA-N Karpoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1(O)C(C)(C)CC(O)CC1(C)O)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C DJOWTWWHMWQATC-KYHIUUMWSA-N 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 102000003992 Peroxidases Human genes 0.000 description 4
- 102000019197 Superoxide Dismutase Human genes 0.000 description 4
- 108010012715 Superoxide dismutase Proteins 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 108040007629 peroxidase activity proteins Proteins 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000003642 reactive oxygen metabolite Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- YDXRLMMGARHIIC-PXNSSMCTSA-N (7s,8s)-7,8-dihydrobenzo[a]pyrene-7,8-diol Chemical compound C1=C2C(C=C[C@@H]([C@H]3O)O)=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 YDXRLMMGARHIIC-PXNSSMCTSA-N 0.000 description 3
- 102000008142 Cytochrome P-450 CYP1A1 Human genes 0.000 description 3
- 108010074918 Cytochrome P-450 CYP1A1 Proteins 0.000 description 3
- 108020005124 DNA Adducts Proteins 0.000 description 3
- 108010046983 Ribonuclease T1 Proteins 0.000 description 3
- 108010083644 Ribonucleases Proteins 0.000 description 3
- 102000006382 Ribonucleases Human genes 0.000 description 3
- DQEPMTIXHXSFOR-ZGXWSNOMSA-N anti-diolepoxide Chemical compound C1=C2C([C@@H]3O[C@@H]3[C@@H]([C@H]3O)O)=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 DQEPMTIXHXSFOR-ZGXWSNOMSA-N 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 210000004671 cell-free system Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000003505 mutagenic effect Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- DQEPMTIXHXSFOR-VCAKUFKGSA-N syn-bpde Chemical compound C1=C2C(C3OC3[C@H]([C@H]3O)O)=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 DQEPMTIXHXSFOR-VCAKUFKGSA-N 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 230000000381 tumorigenic effect Effects 0.000 description 3
- DQEPMTIXHXSFOR-NMLBUPMWSA-N (+)-benzo(a)pyrene-7,8-diol-9,10-epoxide, syn Chemical compound C1=C2C([C@H]3O[C@H]3[C@@H]([C@H]3O)O)=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 DQEPMTIXHXSFOR-NMLBUPMWSA-N 0.000 description 2
- ARSRBNBHOADGJU-UHFFFAOYSA-N 7,12-dimethyltetraphene Chemical compound C1=CC2=CC=CC=C2C2=C1C(C)=C(C=CC=C1)C1=C2C ARSRBNBHOADGJU-UHFFFAOYSA-N 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 108091029865 Exogenous DNA Proteins 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 238000000585 Mann–Whitney U test Methods 0.000 description 2
- FLAQQSHRLBFIEZ-UHFFFAOYSA-N N-Methyl-N-nitroso-4-oxo-4-(3-pyridyl)butyl amine Chemical compound O=NN(C)CCCC(=O)C1=CC=CN=C1 FLAQQSHRLBFIEZ-UHFFFAOYSA-N 0.000 description 2
- 101150053185 P450 gene Proteins 0.000 description 2
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 2
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 125000005605 benzo group Chemical group 0.000 description 2
- 230000036983 biotransformation Effects 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 230000001364 causal effect Effects 0.000 description 2
- 230000002113 chemopreventative effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 229910001882 dioxygen Inorganic materials 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 238000006735 epoxidation reaction Methods 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000000413 hydrolysate Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000219 mutagenic Toxicity 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 229920005547 polycyclic aromatic hydrocarbon Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 150000004053 quinones Chemical class 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 231100000588 tumorigenic Toxicity 0.000 description 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- 150000005208 1,4-dihydroxybenzenes Chemical class 0.000 description 1
- GUQARRULARNYQZ-UHFFFAOYSA-N 2,2,4,4-tetramethyl-1-oxido-3h-pyrrol-1-ium Chemical compound CC1(C)CC(C)(C)[N+]([O-])=C1 GUQARRULARNYQZ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 240000006439 Aspergillus oryzae Species 0.000 description 1
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000004031 Carboxy-Lyases Human genes 0.000 description 1
- 108090000489 Carboxy-Lyases Proteins 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- VFZRZRDOXPRTSC-UHFFFAOYSA-N DMBA Natural products COC1=CC(OC)=CC(C=O)=C1 VFZRZRDOXPRTSC-UHFFFAOYSA-N 0.000 description 1
- 230000007064 DNA hydrolysis Effects 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 230000035519 G0 Phase Effects 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 101001047746 Homo sapiens Lamina-associated polypeptide 2, isoform alpha Proteins 0.000 description 1
- 101001047731 Homo sapiens Lamina-associated polypeptide 2, isoforms beta/gamma Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 102100023981 Lamina-associated polypeptide 2, isoform alpha Human genes 0.000 description 1
- 102000004960 NAD(P)H dehydrogenase (quinone) Human genes 0.000 description 1
- 108020000284 NAD(P)H dehydrogenase (quinone) Proteins 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 101000855355 Ovis aries Cytochrome P450 1A1 Proteins 0.000 description 1
- 241001523956 Parengyodontium album Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000001972 liquid chromatography-electrospray ionisation mass spectrometry Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000004216 mammary stem cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 231100000243 mutagenic effect Toxicity 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 229940097156 peroxyl Drugs 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000015639 rosmarinus officinalis Nutrition 0.000 description 1
- 238000009938 salting Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000005783 single-strand break Effects 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- WVLBCYQITXONBZ-UHFFFAOYSA-N trimethyl phosphate Chemical compound COP(=O)(OC)OC WVLBCYQITXONBZ-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 239000012808 vapor phase Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24D—CIGARS; CIGARETTES; TOBACCO SMOKE FILTERS; MOUTHPIECES FOR CIGARS OR CIGARETTES; MANUFACTURE OF TOBACCO SMOKE FILTERS OR MOUTHPIECES
- A24D3/00—Tobacco smoke filters, e.g. filter-tips, filtering inserts; Filters specially adapted for simulated smoking devices; Mouthpieces for cigars or cigarettes
- A24D3/06—Use of materials for tobacco smoke filters
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/18—Treatment of tobacco products or tobacco substitutes
- A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
- A24B15/30—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24D—CIGARS; CIGARETTES; TOBACCO SMOKE FILTERS; MOUTHPIECES FOR CIGARS OR CIGARETTES; MANUFACTURE OF TOBACCO SMOKE FILTERS OR MOUTHPIECES
- A24D3/00—Tobacco smoke filters, e.g. filter-tips, filtering inserts; Filters specially adapted for simulated smoking devices; Mouthpieces for cigars or cigarettes
- A24D3/06—Use of materials for tobacco smoke filters
- A24D3/14—Use of materials for tobacco smoke filters of organic materials as additive
Definitions
- the invention relates to a cigarette filter containing rosemary extract and a method of reducing DNA damage caused by various harmful agents in cigarette smoke. More specifically, the present invention relates to the use of said filter to reduce DNA damage caused by benzo(a)pyrenes in human cells by the reduction of the human lung benzo(a)pyrene diol epoxide-dG (BPDE-dG) adduct.
- BPDE-dG human lung benzo(a)pyrene diol epoxide-dG
- BPDE-dG human lung benzo(a)pyrene diol epoxide-dG adduct concentrates in bronchial cells. This adduct now is recognized as a critical event in tumorigenesis by benzo(a)pyrenes. Cigarette smoke is a significant contributor to BPDE-dG formation.
- Benzo(a)pyrene is a highly carcinogenic polycyclic aromatic hydrocarbon (PAH) present in emission exhausts, charbroiled food and in small quantity in cigarette smoke, typically less than 10 ng per cigarette.
- PAH polycyclic aromatic hydrocarbon
- BP is one of more than 60 carcinogens in cigarette smoke that is involved in the aetiology of lung cancer.
- BPDE benzo(a)pyrene-7,8-diol-9,10-epoxide
- BPDE benzo(a)pyrene-7,8-diol-9,10-epoxide
- BPDE-dG benzo(a)pyrene-7,8-diol-9,10-epoxide-N 2 -deoxyguanosine
- Rosemary Roamarinus officinalis Labiatae herb and oil, rosemary extracts, carnosic acid and carnosol are commonly used as spice and flavoring agents in food processing for their desirable flavor and high antioxidant activity.
- BP is considered to be a significant carcinogen involved in lung cancer induction in smokers and, as is shown in this study, reactive oxygen species contribute substantially in the formation of the critical lung tumorigenic adduct. While it is both critical to prevent addiction to tobacco and to enhance the efficacy of smoking cessation and reduction programs, these approaches have had little impact.
- the prevention of the formation of BPDE-dG adduct is one approach which may lead to decreasing lung cancer risk in addicted smokers.
- the invention relates to a cigarette filter containing rosemary extract and a method of reducing DNA damage caused by harmful agents in cigarette smoke. More specifically, the present invention provides for the use of said filter to reduce DNA damage caused by benzo(a)pyrenes in human cells by the reduction of the human lung benzo(a)pyrene diol epoxide-dG (BPDE-dG) adduct.
- BPDE-dG human lung benzo(a)pyrene diol epoxide-dG
- Cigarette smoke thus may in this way responsible for the formation of the critical lung tumorigenic adduct.
- modified cigarette filter containing rosemary extract decreases by more than 70% of the BPDE-dG adducts level due to the cigarette smoke in MCF-7 cells. This discovery, I believe is a significant advance in decreasing lung cancer risk in addicted smokers.
- FIG. 1 Principal metabolic pathway and DNA binding of the carcinogen benzo(a)pyrene.
- Benzo(a)pyrene is a tobacco carcinogen that may be converted in vivo enzymatically or by oxygen reactive species to yield DNA-reactive dihydrodiol epoxides.
- Stereoselective generation of the mutagenic (+)-r-7,t-8-dihydroxy-t-9,10-oxy-7,8,9,10-tetrahydro-BP [(+)-anti-BPDE] from ( ⁇ )-BP-7,8-dihydrodiol is catalyzed by cytochrome-P450-dependent monooxygenases (P450) or reactive oxygen species.
- P450 cytochrome-P450-dependent monooxygenases
- FIG. 2 Results obtained by using a cell-free system concomitant with DNA adduction: 6 mg calf thymus DNA in 2 ml water was added to 5 ml CSS with different dilutions and reacted for 2 hours at room temperature with (+)-BP-7,8-diol (final concentration 3.6 ⁇ M). DNA was hydrolyzed and the released BP-tetrol I were measured as outlined in Materials and Methods.
- FIG. 3 (a) Stereochemistry of BP-7,8-diol epoxidation by peroxyl radicals and cytochrome P450 to reactive species (anti-BPDE and syn-BPDE) that can bind to DNA, and (b) acid hydrolysis of DNA to BP-tetrols measured in this study.
- the hydrolysis of ( ⁇ )-anti-BPDE-dG and ( ⁇ )-syn-BPDE leads to the formation of BP-tetrol 1-2 and BP-tetrol II-1 which however are unstable and are converted into BP-tetrol I-1 and BP-tetrol 11-2.
- FIG. 4 Results obtained using MFC-7 cells. 10 ⁇ 10 6 cells/150 cm 2 flask in a total volume of 20 ml were treated for 2 hrs with (+)-BP-7,8-diol (0.2 ⁇ M) alone or in presence of different dilutions of CSS DNA was isolated, hydrolyzed and the released BP-tetrols were measured and the binding levels determined as outlined in Materials and Methods. Two distinct peaks were observed on the chromatograms corresponding to BP-tetrol I and BP-tetrol II derived from ( ⁇ )-anti-BPDE-dG and (+)-syn-BPDE-dG respectively (refs. 32-34).
- FIG. 4 a upper panel, increases of ( ⁇ )-anti-BPDE-dG adducts with CSS dilution
- FIG. 4 b lower panel, increases of 1/(+)-syn-BPDE-dG adduct with CSS dilution.
- FIG. 5 BPDE-dG binding in MCF-7 cells after exposure to BP 2.5 ⁇ M or BP 2.5 CS solution (dilution 20 times) for the time indicated. Cigarette smoke solution was added the last 2 hours during the exposure to BP (Scheme 1). Analysis of BPDE-dG was performed as described in Materials and Methods. Values represent the means of two independent experiments with 4-6 HPLC runs plus Standard. The BPDE-dG value were 11.7 ⁇ 0.5 (mean ⁇ s.d.) ⁇ g of adducts per mg DNA after 12 hours of incubation and 17.6 ⁇ 0.4, 26.1 ⁇ 0.9 after hours and 24 hours respectively.
- the CYP spontaneous metabolism increased theses values to 17.2 ⁇ 0.5, 27.8 ⁇ 0.8 and 42.2 ⁇ 1.0 two hours after the reference time at 12, 18 and 24 hours respectively.
- the addition of cigarette smoke solution (CSS) induced a much more dramatic change during the same two hours period leading to a final BPDE-dG value of 36.9 ⁇ 1.2, 56.7 ⁇ 0.9 and 80.2 ⁇ 1.2 (mean ⁇ s.d.) ⁇ g of adducts per mg after 12, 18 and 24 hours respectively.
- FIG. 6 BPDE-dG binding in MCF-7 cells after exposure to BP 2.5 ⁇ M or BP 2.5 ⁇ M CS solution obtained from standard filter and filter containing rosemary extract. The cigarette smoke solution was added for the last 2 hours during the exposure to BP for the time indicated (Scheme 1). Analysis of BPDE-dG was performed as described in Materials and Methods. The HPLC runs show that there is only one peak on chromatograms which correspond to BP-tetrol I derived from (+)-anti-BPDE-dG. Values represent the means of two independent experiments with 4-6 HPLC runs plus Std.
- the standard CSS system includes 2 ml calf thymus DNA (3 mg/ml), 600 ⁇ l 30 ⁇ M (+) BaP-7,8-diol and 5 ml of diluted CSS with PBS (1:19) at pH 7.4, and was incubated at room temperature for 2 h. Each value was obtained from three independent experiments performed in duplicate. The average error was about 12% in each duplicate experiment.
- the BPDE-dG value of the standard was 56 ⁇ 6.3 (mean ⁇ s.d.) adducts per mg DNA.
- Cigarette smoking is causally associated with a large number of human cancers. Tobacco use is by far the most widespread link between exposure to known carcinogens and death from cancer, and is therefore a model for understanding mechanisms of cancer induction.
- Benzo(a)pyrene is a highly carcinogenic polycyclic aromatic hydrocarbon (PAH) present in emission exhausts, charbroiled food and in small quantity in cigarette smoke, typically less than 10 ng per cigarette.
- PAH polycyclic aromatic hydrocarbon
- BP is one of more than 60 carcinogens in cigarette smoke that is involved in the aetiology of lung cancer. It is metabolically activated into benzo(a)pyrene-7,8-diol-9,10-epoxide (BPDE) which reacts with DNA predominantly at the N 2 -position of guanine to produce primarily N 2 -guanine lesions, e.g. benzo(a)pyrene-7,8-diol-9,10-epoxide-N 2 -deoxyguanosine (BPDE-dG) adduct.
- PAH polycyclic aromatic hydrocarbon
- BPDE-DNA adducts in human tissues has been conclusively established and BPDE-dG adduct concentrated exclusively in bronchial cells and is thus implicated in the initiation of human lung cancer.
- This carcinogen is metabolized by phase I enzymes to a large number of metabolites including phenols, arene oxides, quinones, dihydrodiols, and diol epoxides.
- An overview of BP metabolic way leading to the formation of (+)-anti-BPDE-dG adduct is presented in FIG. 1 .
- the ultimate carcinogen (+)-anti-BPDE is formed from BP by two rounds of cytochrome P450-mediated oxidation.
- the first step of this oxidation leads preferentially to ( ⁇ )-7,8-dihydro-7,8-dihydrobenzo(a)pyrene [( ⁇ )BP-7,8-diol].
- the diol is further oxidised primarily to the highly mutagenic (+)-r7,t-8-dihydroxy-t-9,10-oxy-7,8,9,10-tetrahydro-BP [(+)-anti-BPDE].
- ROS from the cigarette smoke may be in part responsible for the increased BPDE-dG adduct formation.
- My invention provides (i) a means for determining the relative contribution of ROS in cigarette smoke on the activation of BP-7,8-diol in comparison with cytochrome P450; (ii) a means for establishing whether cigarette smoke's ROS promotes the carcinogenic process by contributing to the metabolism of BP-7,8-diol resulting in an increase in the formation of the critical lung BPDE-dG; (iii) a filter containing a scavenger of cigarette free radicals to significantly decrease the formation of BPDE-dG; and (iv) use of said filter to significantly decrease the function of BPDE-dG adducts.
- Proteinase K (EC 3.4.21.64, from Tritirachium album ) was purchased from Sigma (St. Louis, Mo.), RNase T1 (EC 3.1.21.3, from Aspergillus oryzae ) and RNase (DNase free, heterogeneous mixture of ribonucleases from bovine pancreas) were obtained from Boehringer Mannheim (Mannheim, Germany).
- Phosphate-buffered saline (PBS) contained 3.0 mM KCl, 1.5 mM KH 2 HPO 4 , 140 mM NaCl, 8.0 mM Na 2 HPO 4 , (pH 7.4), HPLC-grade water, MeO H, ether and ethanol for spectroscopy from E.
- HPLC High-performance liquid chromatography
- Cigarette Smoke/PBS Solution (CSS). Smoking was performed according to Pryor et al without the Cambridge filter. Essentially the same smoke collecting method has been used earlier by Nakayama et al. The smoke from burning 8 cm of one cigarette (Marlboro) during 3.8 min with the help of constant vacuum generated from a water pump was bubbled through 10 ml of phosphate-buffered saline (PBS) solution which traps both the gas-phase and tar cigarette smoke chemicals. As there were no water-insoluble tar compounds present on the walls of the wash bottles, a major part of the water-soluble compounds from the smoke of a single cigarette was contained in the 10 ml PBS solution.
- PBS phosphate-buffered saline
- CSS cigarette smoke solution
- the level of the resulting ( ⁇ )-anti BPDE-dG adduct was measured (see below). As control an experiment without CSS was performed.
- the human mammary carcinoma cell line MCF-7 was grown in 150-cm 2 cell culture flasks in a total volume of 20 ml minimal essential medium E-MEM supplemented with 10% FCS, 15 mM Hepes buffer, and antibiotics (200 units/ml penicillin, 200 ⁇ g/ml streptomycin, and 25 ⁇ g/ml ampicillin). Cells were maintained and treated at 37° C. in 5% CO 2 /95% air atmosphere.
- DNA Preparation and Hydrolysis DNA isolation from MCF-7 cell pellets was carried out by treatment with RNase, proteinase K, salting procedure (31) and chloroform. Briefly, the cell pellets were resuspended in EDTA-sodium dodecyl sulfate (SDS) buffer [10 mM Tris buffer, 1 mM Na 2 EDTA, 1% SDS (w/v), pH 8] incubated for 1 h at 37° C. with RNase T1 (2000 U/ml) and RNase A (DNase free; 100 ⁇ g/ml) on a shaker (100 rpm). Then proteinase K (300 ⁇ g/ml) was added and the incubation continued overnight at 37° C.
- SDS EDTA-sodium dodecyl sulfate
- the portion of DNA to be hydrolyzed was rinsed with 100% ethanol to remove unbound BP-tetrols.
- the DNA, free of unbound BP-tetrols, was dissolved in water and the DNA concentration was determined by A 260 nm .
- the purity was ascertained by the ratios at A 260 /A 280 and A 260 /A 230 .
- the amount of DNA for analysis was hydrolyzed as described previously by incubation at 90° C. for 4 hour in a final concentration of 0.1 N HCl. This releases tetrols ( FIG. 3 ) from BPDE-DNA adducts with >90% recovery.
- the volume of the hydrolysate for injection was made 700 ⁇ l containing 5-10 ⁇ g DNA.
- BPDE-N 2 -dG adduct level Determinations of BPDE-N 2 -dG adduct level.
- the adduct levels were determined by HPLC-FD as previously described [32,33] using r-7,c-9,t-8,t-10-tetrahydroxy-7,8,9,10-tetrahydrobenzo(a)pyrene (BP-tetrol II-1) as an internal standard [34].
- the hydrolysate was loaded onto a Latex pre-column module (HD-Germany) containing 5 ⁇ m C 18 reverse-phase materiel (Nucleosil 100) equilibrated with 10% MeOH and washed for 20 min with 12 ml 10% MeOH.
- BP tetrol I-1 trans-anti-BP-tetrol
- BP-tetrol II-1 trans-syn-BP-tetrol
- internal standard 36.9 min
- BP tetrol 11-2 cis-syn-BP-tetrol
- the detection limit was 0.5 pg of BP tetrol I-1 and BP-tetrol II-1.
- the level of each BP-tetrol was determined by using a standard curve generated from the fluorescence peak area of authentic BP-tetrol standard analyzed just before the analysis of MCF-7 samples.
- the BP-tetrol-I-1 detected is derived after hydrolysis of (+)-anti-BPDE-DNA adduct.
- the hydrolysis of ( ⁇ )-anti-BPDE-dG leads to the formation of BP-tetrol 1-2, which however is unstable and is converted in BP-tetrol I-1 ( FIG. 3 ) (38).
- the level of the formed ( ⁇ )-anti-BPDE-dG was measured by the quantity of BP-tetrol I-1 found on HPLC runs. Based on the finding that BPDE reacting with DNA produce primarily BPDE-N 2 -dG (7), I assumed that BP-tetrol-I-1 level corresponds to this of BPDE-N 2 -dG.
- the HPLC runs were quantitatively reproducible, and variability between the two assays was lower than 5%.
- BP molecular signature The mechanism of mutagenesis by BP is sufficiently well defined and used as a “molecular signature” to establish the causal nature between particular genetic events in development of tumors and carcinogenic exposure (the “smoking gun”).
- the “BP molecular signature” has major implication for pinpointing the tobacco smoke as the cause of human lung cancer, and for the elaboration of specific strategies to minimize tobacco smoking, or introduce preventive measures.
- Specific agents used in cancer chemoprevention appear to act by inhibiting carcinogen damage to DNA, mutagenesis, tumor promotion and/or tumor progression.
- CS is an aerosol of complex chemical composition containing both organic and inorganic compounds, of which 4800 have been identified so far. Both vapor phase and particulate phase of smoke are known to possess free radicals.
- the radicals in the particulate phase are relatively stable and consist of a hydroquinone, semiquinone, quinone complex
- this complex is an active redox system capable of reducing molecular oxygen to produce superoxide, eventually leading to hydrogen peroxide and hydroxyl radicals.
- CS carcinogens at least 60 different CS carcinogens have been implicated in tumor initiation and promotion; the most potent carcinogens agent contained in CS are BP and NNK (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone).
- the ( ⁇ )-BP-7,8-diol may be metabolized by both pathways and results in the formation of (+)-anti-BPDE, the ultimate form of BP, and ( ⁇ )-syn-BPDE.
- the different pathways can be distinguished by HPLC analysis since the tetrols derived from anti- and syn-BPDE respectively are clearly separated under my conditions.
- Cigarette smoke increased linearly and dose dependently the ROS dependent formation of ( ⁇ )-anti-BPDE-dG ( FIG. 4 a ) and decreased the CYPs dependent formation of (+)-syn-BPDE-dG adduct measured by the formation of BP-tetrol II. This decrease is also dose dependant and the inverse of DNA adducts increased linearly with cigarette smoke concentration ( 4 b ).
- the level of adduct formation at 6 hours was considerably lower than that observed after 12 and 24 hours of exposure.
- the cells were treated for 12 and 18 hours with BP to induce the formation of ( ⁇ )-BP-7,8 diol which is substrate for ROS.
- Indirect confirmation for the preferentially formation of ( ⁇ )-BP-7,8-diol is the absence of BP-tetrol II derived from syn-BPDE on HPLC runs which precursor is (+)-BP-7,8-diol ( FIG. 3 ).
- the cells were then exposed for 2 hours with CSS of cigarette smoke together with BP.
- the HPLC runs show that there is only one peak on chromatograms which correspond to BP-tetrol I derived from (+)-anti-BPDE-dG.
- the difference between cells treated with CSS and those non treated (controls) is presented on FIG. 5 .
- Rosemary Rosmarinus officinalis Labiatae
- DMBA 7,12-dimethylbenz(a)antracene
- Rosemary extracts, carnosic acid and carnosol strongly inhibit phase I enzyme, CYP 450 activities and induce the expression of the phase II enzyme, glutathione S-transferase (GST) and quinone reductase activities.
- Carnosol inhibits nitric oxide (NO) production in activated macrophage.
- the antioxidant property had been reffered to as the mechanistic basis of their protective effects.
- the results presented in FIG. 6 were obtained when the MCF-7 cells were treated with BP.
- Two groups of experiments were performed (A and B). The cells were treated with BP for 12 and 18 hours respectively following with CSS from the two filters for another 2 hours together with BP (Scheme 1).
- two controls for each group were performed: 12 and 14 hours for group A, 18 and 20 hours for group B.
- the CSS from the standard filter double the binding level obtained for 14 and 20 hours.
- rosemary filter strongly impedes the increase obtained by the standard filter, more than 70% in the two groups ( FIG. 6 ).
- the modified filter scavengers ROS and consequently decreases the activation of ( ⁇ )-BP-7,8-diol ( FIG. 3 ).
- rosemary powder may have also other mechanisms to reduce BPDE-dG formation.
- My inventive rosemary cigarette filter therefore is a promising candidate for chemopreventive programs with the aim to reduce BPDE-dG in bronchial epithelial cells.
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cigarettes, Filters, And Manufacturing Of Filters (AREA)
Abstract
The invention relates to a cigarette filter containing rosemary extract and a method of reducing DNA damage caused by various harmful agents in cigarette smoke. More specifically, the present invention relates to the use of said filter to reduce DNA damage caused by benzo (a) pyrenes in human cells by the reduction of the human lung benzo (a) pyrene diol epoxide-dG (BPDE-dG) adduct.
Description
- The invention relates to a cigarette filter containing rosemary extract and a method of reducing DNA damage caused by various harmful agents in cigarette smoke. More specifically, the present invention relates to the use of said filter to reduce DNA damage caused by benzo(a)pyrenes in human cells by the reduction of the human lung benzo(a)pyrene diol epoxide-dG (BPDE-dG) adduct.
- The human lung benzo(a)pyrene diol epoxide-dG (BPDE-dG) adduct concentrates in bronchial cells. This adduct now is recognized as a critical event in tumorigenesis by benzo(a)pyrenes. Cigarette smoke is a significant contributor to BPDE-dG formation.
- Tobacco use is by far the most widespread link between exposure to known carcinogens and death from cancer, and is therefore a model for understanding mechanisms of cancer induction. Benzo(a)pyrene (BP) is a highly carcinogenic polycyclic aromatic hydrocarbon (PAH) present in emission exhausts, charbroiled food and in small quantity in cigarette smoke, typically less than 10 ng per cigarette. BP is one of more than 60 carcinogens in cigarette smoke that is involved in the aetiology of lung cancer. It is metabolically activated into benzo(a)pyrene-7,8-diol-9,10-epoxide (BPDE) which reacts with DNA predominantly at the N2-position of guanine to produce primarily N2-guanine lesions, e.g. benzo(a)pyrene-7,8-diol-9,10-epoxide-N2-deoxyguanosine (BPDE-dG) adduct. The presence of BPDE-DNA adducts in human tissues has been conclusively established and BPDE-dG adduct concentrated exclusively in bronchial cells and thus implicated in the initiation of human lung cancer.
- Rosemary (Roamarinus officinalis Labiatae) herb and oil, rosemary extracts, carnosic acid and carnosol are commonly used as spice and flavoring agents in food processing for their desirable flavor and high antioxidant activity.
- However, prior to the instant invention, there was no recognition that the use of a rosemary extract in a cigarette filter would reduce the DNA damage caused in human cells by benzo(a)pyrenes specifically, the human lung benzo(a)pyrene diol epoxide-dG (BPDE-dG) adduct which adduct now is recognized as a critical event in tumorigenesis by benzo(a)pyrenes.
- BP is considered to be a significant carcinogen involved in lung cancer induction in smokers and, as is shown in this study, reactive oxygen species contribute substantially in the formation of the critical lung tumorigenic adduct. While it is both critical to prevent addiction to tobacco and to enhance the efficacy of smoking cessation and reduction programs, these approaches have had little impact. The prevention of the formation of BPDE-dG adduct is one approach which may lead to decreasing lung cancer risk in addicted smokers.
- The invention relates to a cigarette filter containing rosemary extract and a method of reducing DNA damage caused by harmful agents in cigarette smoke. More specifically, the present invention provides for the use of said filter to reduce DNA damage caused by benzo(a)pyrenes in human cells by the reduction of the human lung benzo(a)pyrene diol epoxide-dG (BPDE-dG) adduct.
- It has been found that the amount of (−)-anti-BPDE-dG adduct increases linearly with concentration of cigarette smoke in the presence of (+)-BP-7,8-diol. Catalase and superoxide dismutase inhibit its formation by more than 80%. When MCF-7 cells are treated for 2 hours with the (+)-BP-7,8-diol, cigarette smoke increases dose dependently the formation of (−)-anti-BPDE-dG and decreases the CYPs dependent formation of (+)-syn-BPDE, the adduct.
- I have treated cells for up to one day with benzo(a)pyrene and then exposed them for 2 hours with cigarette smoke. During these 2 hours, I have discovered that there is twice the increase in the adduct formation in cells treated with cigarette smoke in comparison to levels in non treated cells due to CYPs activity. Thus, I have found that cigarette smoke activates by reactive oxygen species which it contains the second step of benzo(a)pyrene metabolic way leading to the formation of BPDE-dG adduct.
- Cigarette smoke thus may in this way responsible for the formation of the critical lung tumorigenic adduct.
- Finally, I have found that modified cigarette filter containing rosemary extract decreases by more than 70% of the BPDE-dG adducts level due to the cigarette smoke in MCF-7 cells. This discovery, I believe is a significant advance in decreasing lung cancer risk in addicted smokers.
-
FIG. 1 . Principal metabolic pathway and DNA binding of the carcinogen benzo(a)pyrene. Benzo(a)pyrene is a tobacco carcinogen that may be converted in vivo enzymatically or by oxygen reactive species to yield DNA-reactive dihydrodiol epoxides. Stereoselective generation of the mutagenic (+)-r-7,t-8-dihydroxy-t-9,10-oxy-7,8,9,10-tetrahydro-BP [(+)-anti-BPDE] from (−)-BP-7,8-dihydrodiol is catalyzed by cytochrome-P450-dependent monooxygenases (P450) or reactive oxygen species. Subsequent reaction of this electrophilic intermediate with genomic DNA produce stable adduct between dihydrodiol epoxide and the exocyclic amino group of guanosine. This kind of DNA lesion may be converted into mutations within the following replication cycle unless repair of this adduct is produced. -
FIG. 2 . Results obtained by using a cell-free system concomitant with DNA adduction: 6 mg calf thymus DNA in 2 ml water was added to 5 ml CSS with different dilutions and reacted for 2 hours at room temperature with (+)-BP-7,8-diol (final concentration 3.6 μM). DNA was hydrolyzed and the released BP-tetrol I were measured as outlined in Materials and Methods. -
FIG. 3 . (a) Stereochemistry of BP-7,8-diol epoxidation by peroxyl radicals and cytochrome P450 to reactive species (anti-BPDE and syn-BPDE) that can bind to DNA, and (b) acid hydrolysis of DNA to BP-tetrols measured in this study. The hydrolysis of (−)-anti-BPDE-dG and (−)-syn-BPDE leads to the formation of BP-tetrol 1-2 and BP-tetrol II-1 which however are unstable and are converted into BP-tetrol I-1 and BP-tetrol 11-2. -
FIG. 4 . Results obtained using MFC-7 cells. 10×106 cells/150 cm2 flask in a total volume of 20 ml were treated for 2 hrs with (+)-BP-7,8-diol (0.2 μM) alone or in presence of different dilutions of CSS DNA was isolated, hydrolyzed and the released BP-tetrols were measured and the binding levels determined as outlined in Materials and Methods. Two distinct peaks were observed on the chromatograms corresponding to BP-tetrol I and BP-tetrol II derived from (−)-anti-BPDE-dG and (+)-syn-BPDE-dG respectively (refs. 32-34). Values represent the means plus Std of two independent experiments with 3-4 HPLC runs:FIG. 4 a, upper panel, increases of (−)-anti-BPDE-dG adducts with CSS dilution;FIG. 4 b, lower panel, increases of 1/(+)-syn-BPDE-dG adduct with CSS dilution. -
FIG. 5 . BPDE-dG binding in MCF-7 cells after exposure to BP 2.5 μM or BP 2.5 CS solution (dilution 20 times) for the time indicated. Cigarette smoke solution was added the last 2 hours during the exposure to BP (Scheme 1). Analysis of BPDE-dG was performed as described in Materials and Methods. Values represent the means of two independent experiments with 4-6 HPLC runs plus Standard. The BPDE-dG value were 11.7±0.5 (mean±s.d.) □g of adducts per mg DNA after 12 hours of incubation and 17.6±0.4, 26.1±0.9 after hours and 24 hours respectively. The CYP spontaneous metabolism increased theses values to 17.2±0.5, 27.8±0.8 and 42.2±1.0 two hours after the reference time at 12, 18 and 24 hours respectively. The addition of cigarette smoke solution (CSS) induced a much more dramatic change during the same two hours period leading to a final BPDE-dG value of 36.9±1.2, 56.7±0.9 and 80.2±1.2 (mean±s.d.) □g of adducts per mg after 12, 18 and 24 hours respectively. -
FIG. 6 . BPDE-dG binding in MCF-7 cells after exposure to BP 2.5 μM or BP 2.5 μM CS solution obtained from standard filter and filter containing rosemary extract. The cigarette smoke solution was added for the last 2 hours during the exposure to BP for the time indicated (Scheme 1). Analysis of BPDE-dG was performed as described in Materials and Methods. The HPLC runs show that there is only one peak on chromatograms which correspond to BP-tetrol I derived from (+)-anti-BPDE-dG. Values represent the means of two independent experiments with 4-6 HPLC runs plus Std. -
Scheme 1. MCF-7 cells were treated with BP for 12 hrs and 18 hrs following with cigarette smoke for another 2 hours together with BP (experiments A and B respectively). The goal of this experiment was to activate at different times the BP to produce BP-7,8-diol and after treat the cells with cigarette smoke and follow its effect during the last 2 hours. The control represents cells treated only with BP. -
TABLE 1 Effect of scavengers on BPDE-dG level caused by cigarette smoke in a cell-free system % BPDE-dG relative Treatment to standard CS Standard CSS 100 +Superoxide Dismutase SOD (20 μg) 16 +Catalase (4 μg) 12 +Inactivated Catalase (4 μg) 100 Romarin filtered CSS instead Standard CSS 42 - The standard CSS system includes 2 ml calf thymus DNA (3 mg/ml), 600 μl 30 μM (+) BaP-7,8-diol and 5 ml of diluted CSS with PBS (1:19) at pH 7.4, and was incubated at room temperature for 2 h. Each value was obtained from three independent experiments performed in duplicate. The average error was about 12% in each duplicate experiment. The BPDE-dG value of the standard was 56±6.3 (mean±s.d.) adducts per mg DNA.
- Cigarette smoking is causally associated with a large number of human cancers. Tobacco use is by far the most widespread link between exposure to known carcinogens and death from cancer, and is therefore a model for understanding mechanisms of cancer induction.
- Benzo(a)pyrene (BP) is a highly carcinogenic polycyclic aromatic hydrocarbon (PAH) present in emission exhausts, charbroiled food and in small quantity in cigarette smoke, typically less than 10 ng per cigarette. BP is one of more than 60 carcinogens in cigarette smoke that is involved in the aetiology of lung cancer. It is metabolically activated into benzo(a)pyrene-7,8-diol-9,10-epoxide (BPDE) which reacts with DNA predominantly at the N2-position of guanine to produce primarily N2-guanine lesions, e.g. benzo(a)pyrene-7,8-diol-9,10-epoxide-N2-deoxyguanosine (BPDE-dG) adduct.
- The presence of BPDE-DNA adducts in human tissues has been conclusively established and BPDE-dG adduct concentrated exclusively in bronchial cells and is thus implicated in the initiation of human lung cancer.
- This carcinogen is metabolized by phase I enzymes to a large number of metabolites including phenols, arene oxides, quinones, dihydrodiols, and diol epoxides. An overview of BP metabolic way leading to the formation of (+)-anti-BPDE-dG adduct is presented in
FIG. 1 . - In more detail, the ultimate carcinogen (+)-anti-BPDE is formed from BP by two rounds of cytochrome P450-mediated oxidation. The first step of this oxidation leads preferentially to (−)-7,8-dihydro-7,8-dihydrobenzo(a)pyrene [(−)BP-7,8-diol]. The diol is further oxidised primarily to the highly mutagenic (+)-r7,t-8-dihydroxy-t-9,10-oxy-7,8,9,10-tetrahydro-BP [(+)-anti-BPDE]. Numerous studies have clearly identified the [(+)-anti-BPDE] as the primary carcinogenic metabolite of BP exhibiting enhanced mutagenic activity in vitro and in vivo. Most previous studies of genetic variation in metabolism of lung carcinogens have focused on metabolic activation by various cytochromes P450s, although expression of these enzymes in lung is generally low). The activation of BP-7,8-diol by lung epithelial cells is not caused solely by classic CYPs/GSTs dependent biotransformation processes, but also involves several metabolic routes other than CYPs. These include, lipooxygenase, lipid-peroxidation products and peroxidase-dependent pathways, COX-1 and COX-2.
- Increasing evidence suggests the causal significance of tobacco free radicals in lung cancer induction in smokers. Each puff of smoke forms over 10 trillion free radicals present in smoke, which may contribute to both tumor initiation as well as promotion of various forms of human cancer caused by repeated attacks from ROS on cellular macromolecules. The major free radical species are postulated to be an equilibrium mixture of semiquinones, hydroquinones and quinones. It is suggested that this free radical complex causes redox cycling that generates superoxide anion from molecular oxygen and leads to the formation of hydrogen peroxide and hydroxyl radical. These reactive species cause DNA nicking and single-strand breaks in DNA of cultured rodent and human cells. Quinone-associated redox cycling may also be involved in these effects; hydroquinone and catechol are believed to play a major role.
- I have discovered that cigarette smoke can activate by its oxygen generated radicals the second step of the BP metabolic pathway leading to the formation of BPDE-dG adduct, presumably by metabolism of the formed in the cells (−)-BP-7,8-diol to (+)-r-7,t-8-dihydroxy-t-9,10-oxy-7,8,9,10-tetrahydro-BP [(+)-anti-BPDE] (
FIG. 1 ). - I have also discovered that this activation is at least twice higher than this obtained with CYPs machinery.
- Further, I have discovered that ROS from the cigarette smoke may be in part responsible for the increased BPDE-dG adduct formation.
- I have also found that a filter containing a formulated rosemary powder can reduce considerably the BPDE-dG level due CS oxygen generated radical, and that my discoveries can be used for cigarette filters which reduce the formation of carcinogenic BPDE-dG adduct in bronchial epithelial cells.
- My invention provides (i) a means for determining the relative contribution of ROS in cigarette smoke on the activation of BP-7,8-diol in comparison with cytochrome P450; (ii) a means for establishing whether cigarette smoke's ROS promotes the carcinogenic process by contributing to the metabolism of BP-7,8-diol resulting in an increase in the formation of the critical lung BPDE-dG; (iii) a filter containing a scavenger of cigarette free radicals to significantly decrease the formation of BPDE-dG; and (iv) use of said filter to significantly decrease the function of BPDE-dG adducts.
- Chemicals. Proteinase K (EC 3.4.21.64, from Tritirachium album) was purchased from Sigma (St. Louis, Mo.), RNase T1 (EC 3.1.21.3, from Aspergillus oryzae) and RNase (DNase free, heterogeneous mixture of ribonucleases from bovine pancreas) were obtained from Boehringer Mannheim (Mannheim, Germany). Phosphate-buffered saline (PBS) contained 3.0 mM KCl, 1.5 mM KH2HPO4, 140 mM NaCl, 8.0 mM Na2HPO4, (pH 7.4), HPLC-grade water, MeO H, ether and ethanol for spectroscopy from E. Merck, Darmstadt, Germany. If not stated otherwise, the others chemicals were purchased from Siyma (L'Isle d'Abeau Chesnes, France), Boehringer Ingelheim (Heidelberg, Germany) and Boehringer Mannheim (Mannheim, Germany). All BP metabolite standards were obtained from National Cancer Institute, Chemical Carcinogen Reference Standard Repository Midwest Research Institute (Kansas City, Mo.).
- Apparatus. High-performance liquid chromatography (HPLC) was carried out with a Hewlett-Packard high pressure isocratic and gradient systems (Waldborn, Germany) equipped with a Shimadzu RF-10AXL fluorescence detector linked to a Hewlett-Packard integrator.
- Preparation of Cigarette Smoke/PBS Solution (CSS). Smoking was performed according to Pryor et al without the Cambridge filter. Essentially the same smoke collecting method has been used earlier by Nakayama et al. The smoke from burning 8 cm of one cigarette (Marlboro) during 3.8 min with the help of constant vacuum generated from a water pump was bubbled through 10 ml of phosphate-buffered saline (PBS) solution which traps both the gas-phase and tar cigarette smoke chemicals. As there were no water-insoluble tar compounds present on the walls of the wash bottles, a major part of the water-soluble compounds from the smoke of a single cigarette was contained in the 10 ml PBS solution. This aqueous solution named cigarette smoke solution (CSS) was reacted immediately with exogenous DNA or added to MCF-7 cells in culture in the presence of benzo(a)pyrene or its proximate metabolite (+)-BaP-7,8-diol. Different dilutions of CSS were used (see below).
- Incorporation of a Rosemary Powder Extract into the Cigarette Filter. The filter of the conventional cigarette was removed and 40 mg of a rosemary powder extract, was introduced in the place free from the filter near to the cigarette itself. After this operation, the filter was reinstalled. The effect of this filter was evaluated by mass spectrometry. Briefly the cigarette smoke was bubbled in an organic solution containing 3,3,5,5-tetramethyl-1-pyrroline-N-oxide TMPD) a spin trap adduct. The amount of hydroxyl radical adduct was then quantified using liquid chromatography, mass spectrometry. Under the smoking conditions used a 30% decrease in the hydroxyl radical was observed.
- Reaction of Exogenous DNA with (+)-BP-7,8-Diol in Presence of Diluted Cigarette Smoking Solution (CSS). 2 ml calf thymus DNA (3 mg/ml) was added to 5 ml diluted 20 times CSS and reacted for 2 hours at room temperature with (+)-BP-7,8-diol (final concentration 3.6 μM) according to the following reaction:
-
DNA+[(+)-BP-7,8-diol]+CSS→(−)-anti-BPDE-N2-dG - The level of the resulting (−)-anti BPDE-dG adduct was measured (see below). As control an experiment without CSS was performed.
- Cell Culture Conditions and Treatment. The human mammary carcinoma cell line MCF-7 was grown in 150-cm2 cell culture flasks in a total volume of 20 ml minimal essential medium E-MEM supplemented with 10% FCS, 15 mM Hepes buffer, and antibiotics (200 units/ml penicillin, 200 μg/ml streptomycin, and 25 μg/ml ampicillin). Cells were maintained and treated at 37° C. in 5% CO2/95% air atmosphere.
- After MCF-7 cells had covered 90% of the surface area of the flasks, (2-3 days after splitting of a confluent culture), the medium was replaced with 20 ml of fresh medium containing 10% serum. Twenty four hours later, near-confluent cells e.g. more than 90% of cells in G0/G1 phase were treated with DMSO alone or with carcinogen (see below) dissolved in DMSO and cigarette smoke/PBS (CSS see above). The final concentration of DMSO did not exceed 0.1% of the total incubation volume. Control samples included in each incubation set were treated with DMSO alone.
- a) Treatment of MCF-7 Cells with (±)-BP-7,8-Diol and Cigarette Smoke. Cells were treated for 2 hours with (—O-BP-7,8-diol (0.2 μM) alone or in presence of different dilutions of CSS. The (+)-BaP-7,8-diol was activated by ROO° generated from the CS and cell CYP's to form (−)-anti-BPDE-dG and (+)-syn-BPDE-dG respectively. Their levels were measured by the formation of BP-tetrol I-1 and BP-tetrol 11-2 (see below and
FIG. 3 ). - b) Time/Dose Exposure Experiments with BP. To characterize time/dose exposure to BP and BPDE-dG level, cells (10×106 cells/150 cm2 flask, total volume of 20 ml) were treated with medium containing final concentration of 1.25, 2.5 and 5.0 μM each for 6, 12, 18 and 24 hours (two flasks/dose/time point). BPDE-dG adduct formed in the cells increase linearly in a dose- and time-dependent manner to as was shown also by others (30). On the basis of the results obtained we choose 2.5 μM as working concentration for BP.
- c) Treatment of MCF-7 Cells with BP and Cigarette Smoke. To see the effect of CS concentration, the experience A of
scheme N o 1 was performed with different CSS dilutions (1:79; 1:39; 1:19; 1:9 vol/vol). On the basis of the results obtained from this experience I choose 1:19 (vol/vol) dilution as working CS concentration. Thus, the cells (see above “Cell Culture and Treatment”) were treated with BP (2.5 μM) and CSS (dilution 1:19 vol/vol) according to Scheme 1 (See FIG. 6—Scheme 1). - All incubation sets were repeated 2-3 times with duplicate samples. At the end of treatment, cells were examined microscopically for morphological changes, then harvested by trypsinization with 0.05% trypsin-EDTA (0.05% trypsin, 0.14 M NaCl, 3 mM KCl, 0.1 M Na2HPO4, 1.5 mM K2HPO4, 0.5 mM EDTA). After addition of an equal volume of medium containing 10% FCS, the cells were centrifuged at 1000 g, washed three times with PBS, and the cell pellet then stored frozen at −20° C. The viability of the cells treated with BP and cigarette smoke or (+)-BP-7,8-diol and cigarette smoke was roughly 90% at the time of harvesting as determined by a Trypan blue exclusion assay. The doses used did not show any cytotoxicity as measured by lactate dehydrogenase activity assay (ELISA Kit, Boehringer, Mannheim).
- DNA Preparation and Hydrolysis. DNA isolation from MCF-7 cell pellets was carried out by treatment with RNase, proteinase K, salting procedure (31) and chloroform. Briefly, the cell pellets were resuspended in EDTA-sodium dodecyl sulfate (SDS) buffer [10 mM Tris buffer, 1 mM Na2EDTA, 1% SDS (w/v), pH 8] incubated for 1 h at 37° C. with RNase T1 (2000 U/ml) and RNase A (DNase free; 100 μg/ml) on a shaker (100 rpm). Then proteinase K (300 μg/ml) was added and the incubation continued overnight at 37° C. After digestion, 6M NaCl was added to have final concentration of 1M followed by a centrifugation at 10000 g. DNA in the supernal was precipitated with 2 vol. ethanol, washed with 70%, 100% ethanol, ether, dried and dissolved in 10 mM Tris buffer. Again, RNase A (100 μg/ml) and RNase T1 (2000 U/ml) were added and the solution incubated at 37° C. for 1 h. followed by proteinase K (100 μg/ml) for another 2 hours at 37° C. The solution was extracted once with chloroform, centrifuged and the solution was made 1M NaCl. DNA was precipitated with 2 vol. cold ethanol.
- The portion of DNA to be hydrolyzed was rinsed with 100% ethanol to remove unbound BP-tetrols. The DNA, free of unbound BP-tetrols, was dissolved in water and the DNA concentration was determined by A260 nm. The purity was ascertained by the ratios at A260/A280 and A260/A230. The amount of DNA for analysis was hydrolyzed as described previously by incubation at 90° C. for 4 hour in a final concentration of 0.1 N HCl. This releases tetrols (
FIG. 3 ) from BPDE-DNA adducts with >90% recovery. The volume of the hydrolysate for injection was made 700 μl containing 5-10 μg DNA. - Determinations of BPDE-N2-dG adduct level. The adduct levels were determined by HPLC-FD as previously described [32,33] using r-7,c-9,t-8,t-10-tetrahydroxy-7,8,9,10-tetrahydrobenzo(a)pyrene (BP-tetrol II-1) as an internal standard [34]. The hydrolysate was loaded onto a Latex pre-column module (HD-Germany) containing 5 μm C18 reverse-phase materiel (Nucleosil 100) equilibrated with 10% MeOH and washed for 20 min with 12
ml 10% MeOH. Subsequently, the pre-column was switched by a Valco Instruments switching valve to flow over a 4.6 mm×25 cm 5 μm C18 reverse-phase (Nucleosil 100) analytical column (Alltech GmbH, Unterhaching, Germany). The products obtained by hydrolysis were eluted with the following MeOH/H2O gradient: 50%, 0-17 min; 50 to 60%, 17-32 min; 60%, 32-42 min; 60 to 100%, 42-57 min. Retention times of the BP tetrols were: BP tetrol I-1 (trans-anti-BP-tetrol) (35.2 min); BP-tetrol II-1 (trans-syn-BP-tetrol), internal standard (36.9 min); BP tetrol 11-2 (cis-syn-BP-tetrol) (42.3 min). Fluorescence was assessed at an excitation wavelength of 344 mm and emission wavelength of 398 nm. As I did not detect the formation of BP tetrol II-1 in separate analysis of MCF-7 samples, I used it as internal standard (2 pg added to each HPLC run) for verification of the relative retention time. The detection limit was 0.5 pg of BP tetrol I-1 and BP-tetrol II-1. The level of each BP-tetrol was determined by using a standard curve generated from the fluorescence peak area of authentic BP-tetrol standard analyzed just before the analysis of MCF-7 samples. The BP-tetrol-I-1 detected is derived after hydrolysis of (+)-anti-BPDE-DNA adduct. The hydrolysis of (−)-anti-BPDE-dG leads to the formation of BP-tetrol 1-2, which however is unstable and is converted in BP-tetrol I-1 (FIG. 3 ) (38). Thus, the level of the formed (−)-anti-BPDE-dG was measured by the quantity of BP-tetrol I-1 found on HPLC runs. Based on the finding that BPDE reacting with DNA produce primarily BPDE-N2-dG (7), I assumed that BP-tetrol-I-1 level corresponds to this of BPDE-N2-dG. The level of BPDE bound to MCF-7 DNA was quantified in duplicates. The adduct level was calculated from theequitation 1 pmol/mg DNA/3.125=1 adduct per 106 nucleotide. The HPLC runs were quantitatively reproducible, and variability between the two assays was lower than 5%. - The mechanism of mutagenesis by BP is sufficiently well defined and used as a “molecular signature” to establish the causal nature between particular genetic events in development of tumors and carcinogenic exposure (the “smoking gun”). The “BP molecular signature” has major implication for pinpointing the tobacco smoke as the cause of human lung cancer, and for the elaboration of specific strategies to minimize tobacco smoking, or introduce preventive measures. Specific agents used in cancer chemoprevention appear to act by inhibiting carcinogen damage to DNA, mutagenesis, tumor promotion and/or tumor progression.
- I have explored the relative role of CS on the biotransformation of BP-7,8-diol to BPDE capable of forming stable DNA adduct in human cells. Numerous studies have demonstrated that stable PAH-DNA adducts can lead to mutations through mis-incorporation of nucleotides or deletion. CS is an aerosol of complex chemical composition containing both organic and inorganic compounds, of which 4800 have been identified so far. Both vapor phase and particulate phase of smoke are known to possess free radicals. While the gas phase radicals are generally short-lived the radicals in the particulate phase are relatively stable and consist of a hydroquinone, semiquinone, quinone complex, this complex is an active redox system capable of reducing molecular oxygen to produce superoxide, eventually leading to hydrogen peroxide and hydroxyl radicals. In addition, at least 60 different CS carcinogens have been implicated in tumor initiation and promotion; the most potent carcinogens agent contained in CS are BP and NNK (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone).
- The Effect of Cigarette Smoke on (+)-anti-BPDE-dG Using a Cell-Free System Concomitant with DNA Adduction. To elucidate the mechanism of BPDE-dG formation dependent from active oxygen generated from cigarette smoke, I looked for this adduct in cell-free in vitro system concomitant with DNA adduction. The CSS solution containing the gas-phase and tar cigarette smoke radicals was immediately reacted with DNA in the presence of (+)-BP-7,8-diol (see protocol above). The results from this experiment show that CS can oxidize the (+)-BP-7,8 diol to (−)-anti-BPDE which in turn form the (−)-anti-BPDE-dG adduct. The amount of (−)-anti-BPDE-dG increased linearly and dose dependently (See
FIG. 2 ). - Previously it was found that large amounts of active oxygen such as H2O2 and O2 − were generated from cigarette smoke after trapping the smoke in PBS. This active oxygen generated from cigarette smoke might be responsible for the observed formation of (−)-anti-BPDE-dG. To verify this, I checked the effect of catalase and superoxide dismutase (SOD) on the (−)-anti-BPDE-dG produced, and found that the both enzymes inhibited the formation of the adduct. Inactivated catalase showed no effect (Table 1). From these results I concluded that cigarette smoke can oxidize (+)-BP-7,8-diol, thus forming (−)-anti-BPDE-dG, and that such capacity can be explained mainly by the action of oxygen generated from cigarette smoke.
- The Effect of Cigarette Smoke on (−)-anti-BPDE-dG Adduct Formed in MCF-7 Cells Treated with (+)-BP-7,8-diol. Two independent pathways have been shown to participate in the metabolism of BP-7,8-diol to BPDE (
FIG. 3 ). The cytochrome P450 dependent metabolism of the (+)-enantiomer leads preferentially to (+)-syn-BPDE whereas the pathway involving haem-containing proteins in conjunction with a peroxide (e.g. lipid peroxide) preferentially results in (−)-anti-BPDE. The (−)-BP-7,8-diol on the other hand, may be metabolized by both pathways and results in the formation of (+)-anti-BPDE, the ultimate form of BP, and (−)-syn-BPDE. The different pathways can be distinguished by HPLC analysis since the tetrols derived from anti- and syn-BPDE respectively are clearly separated under my conditions. - To investigate further the role of cigarette smoke dependent epoxidation of (+)-BP-7,8-diol leading to the formation of (−)-anti-BPDE that form with DNA (−)-anti-BPDE-dG adduct, human mammary cell line MCF-7 was used. The reason for which I used MCF-7 cells to see the effect of cigarette smoke ROS on the activation of (+)-BP-7, 8 diol was that these cells have little peroxidase activity. The cells were treated with the (+)-BP-7,8-diol, a stereochemical probe which can distinguish the adducts formed by ROS and CYPs dependent ways (
FIG. 3 ). Two distinct peaks were observed on the chromatograms corresponding to BP-tetrol I and BP-tetrol II derived from (−)-anti-BPDE-dG and (+)-syn-BPDE-dG respectively (refs. 32-34). Cigarette smoke increased linearly and dose dependently the ROS dependent formation of (−)-anti-BPDE-dG (FIG. 4 a) and decreased the CYPs dependent formation of (+)-syn-BPDE-dG adduct measured by the formation of BP-tetrol II. This decrease is also dose dependant and the inverse of DNA adducts increased linearly with cigarette smoke concentration (4 b). The inhibitory effect of CS on CYPs dependent formation of (+)-syn-BPDE-dG and increased formation of (−)-anti-BPDE-dG adduct confirm the role of the oxygen generated from the cigarette smoke in the formation of (−)-anti-BPDE-dG adduct. - Other studies showed that induced CYPs activity was impaired by the oxidative challenge. The mechanism underlying such a phenomenon could be a down-regulation of cytochrome P4501A1 gene. Having little peroxidase activity may lead MCF cells under “stress” conditions to increased DNA damage and reduced repair capacity. Consequently this may cause an increase of BPDE-DNA adducts independently from BP-7,8-diol activation.
- The Effect of Cigarette Smoke on BPDE-dG Adduct Formed in Cells Treated with BP. Previous studies with MCF-7 cell cultures revealed that these cells possess inducible P4501B1 and P4501A1 activity. The presence of P450 catalyzed metabolic turnover of BP and the absence of detectable peroxidase activity in MCF-7 cells, allowed the evaluation of the role of cigarette smoke oxygen radicals on BP activation in human cell cultures. MCF-7 cells have high CYP1A1 enzyme activity for the metabolic activation of BP leading to the formation of (−)-BP-7,8-diol and consequently to (+)-anti-BPDE-dG (
FIG. 1 ). The level of adduct formation at 6 hours was considerably lower than that observed after 12 and 24 hours of exposure. After treatment with 2.5 μM BP for 6 hours approximately 2000 pg adducts per mg DNA were formed, whereas more than 11000 pg and more than 20000 pg adducts per mg DNA were present after 12 hours and 24 hours respectively (Wilcoxon Rank Sum Test gives p=0.0022). - The cells were treated for 12 and 18 hours with BP to induce the formation of (−)-BP-7,8 diol which is substrate for ROS. Indirect confirmation for the preferentially formation of (−)-BP-7,8-diol is the absence of BP-tetrol II derived from syn-BPDE on HPLC runs which precursor is (+)-BP-7,8-diol (
FIG. 3 ). The cells were then exposed for 2 hours with CSS of cigarette smoke together with BP. The HPLC runs show that there is only one peak on chromatograms which correspond to BP-tetrol I derived from (+)-anti-BPDE-dG. The difference between cells treated with CSS and those non treated (controls) is presented onFIG. 5 . As mentioned above the cell line used in this study maintained the capability to lower the CYP1A1 expression after oxidative challenge by CS. The suppression of cytochrome P450 presumably lowers activation of BP to (−)-BP-7,8-diol and (+)-anti-BPDE. Thus the increased difference by CS is due to the increased metabolism of (−)-BaP-7,8 diol by ROS generated from CS. Wilcoxon Rank Sum Test gives p=0.0022 for treated with CS vs controls for 14 hours and 20 hours respectively. Recently Dramatic damage by BP of DNA occurs in human bronchial epithelial cells forming BPDE-dG adduct which could be considered as “critical” for the initiation of human lung cancer bronchial epithelial cells. Thus, active oxygen species generated in cigarette smoke could play an important role in the formation of this “critical” adduct in bronchial epithelial cells (FIG. 1 ). - The Effect of Filter Containing Rosemary Extract on the Formation of BPDE-dG Adduct. Rosemary (Rosmarinus officinalis Labiatae) herb and oil are commonly used as spice and flavoring agents in food processing for its desirable flavor and high antioxidant activity. Topical application of rosemary extract, carnasol or ursolic acid to mouse skin inhibited the covalent binding of benzo(a)pyrene to epidermal DNA, tumor initiation by 7,12-dimethylbenz(a)antracene (DMBA), TPA-induced tumor promotion, ornitine decarboxylase activity and inflammation. Rosemary extracts were proved to be efficient not only in the promotion phase but also in the initiation phase. Rosemary extracts, carnosic acid and carnosol strongly inhibit phase I enzyme, CYP 450 activities and induce the expression of the phase II enzyme, glutathione S-transferase (GST) and quinone reductase activities. Carnosol inhibits nitric oxide (NO) production in activated macrophage. The antioxidant property had been reffered to as the mechanistic basis of their protective effects.
- With the aim of removing free radicals and reactive oxygen species in the cigarette smoke a small amount of rosemary powder was incorporated in a standard filter (see Materials). The decrease in free radicals in the condensate induced by the filters incorporating a rosemary extract was estimated by the quantitation of the hydroxyl radical content of CSS with a spin trap (TMPO) using LC-ESI-MS/MS. Under the smoking conditions used a 30% decrease in the hydroxyl radical was observed. Due to the efficiency of this filter to reduce the level of the free radicals in cigarette smoke, as compared to a comparable standard Marlboro filter without the additive, I compared the effect of CS passed through this filter in comparison to the standard filter on the formation of BPDE-dG using MCF-7 cells.
- The results presented in
FIG. 6 were obtained when the MCF-7 cells were treated with BP. Two groups of experiments were performed (A and B). The cells were treated with BP for 12 and 18 hours respectively following with CSS from the two filters for another 2 hours together with BP (Scheme 1). To evaluate the CYPs dependent increase of the adduct during these last 2 hours, two controls for each group were performed: 12 and 14 hours for group A, 18 and 20 hours for group B. The CSS from the standard filter double the binding level obtained for 14 and 20 hours. - However, the rosemary filter strongly impedes the increase obtained by the standard filter, more than 70% in the two groups (
FIG. 6 ).). The modified filter scavengers ROS and consequently decreases the activation of (−)-BP-7,8-diol (FIG. 3 ). Aside from the reduction of the free radicals, rosemary powder may have also other mechanisms to reduce BPDE-dG formation. - Using whole rosemary extract (6 μg·ml−1) also inhibits CYP1A1 activity and DNA adduct formation by 80% after 6 hours co-incubation with 1.5 μM BP in human bronchial epithelial cells (REAS-2B). Thus, using filters which decrease the amount of the free radicals to reduce the formation of the critical tumorogenic adduct are a significant benefit for the addicted smokers.
- My inventive rosemary cigarette filter therefore is a promising candidate for chemopreventive programs with the aim to reduce BPDE-dG in bronchial epithelial cells.
- It will be understood that the above description of the present invention is susceptible to various modifications, changes and adaptations, and the same are intended to be comprehended within the meaning and range of equivalents of the appended claims. The most obvious modification, for example, is the use of various gel materials as the electroresponsive composition of matter.
- It will thus be seen that the objects set forth above, among those made apparent from the preceding description, are efficiently attained and, since certain changes may be made in carrying out the above method (process) without departing from the spirit and scope of the invention, it is intended that all matter contained in the above description shall be interpreted as illustrative and not in a limiting sense.
- It is also to be understood that the following claims are intended to cover all of the generic and specific features of the invention herein described and all statements of the scope of the invention which, as a matter of language, might be said to fall there between.
Claims (10)
1. A method for reducing human lung benzo(a)pyrene diol epoxide-dG (BPDE-dG) adducts from cigarette smoke generated by smoking a cigarette having a filter, said method comprising the steps of passing the cigarette smoke through the filter wherein said filter is impregnated by an extract of a plant from the Labiatae family wherein said extract comprises polyphenol compounds or derivatives thereof.
2. The method according to claim 1 , wherein the plant is rosemary.
3. The method according to claim 1 wherein the extract is generated by extraction with an alcoholic solvent or an aqueous alcoholic solvent.
4. A method for reducing human lung benzo(a)pyrene diol epoxide-dG (BPDE-dG) adducts from cigarette smoke generated by smoking a cigarette having a filter, said method comprising the steps of passing the cigarette smoke through the filter wherein said filter is impregnated by a mixture comprising at least one polyphenol compound or its derivative.
5. The method according to claim 4 , wherein the mixture comprises at least one polyphenol compound or a derivative thereof selected from the group consisting of carnosol, rosmanol, rosmarinic acid, and carnosic acid.
6. The method according to claim 5 , wherein the mixture comprises carnosol, carnosic acid, rosmarinic acid, and rosemanol.
7. The method according to claim 6 , wherein the mixture comprises carnosic acid or carnosol.
8. The method according to claim 7 , wherein the filter comprises from 0.5 g to 0.1 mg of at least one polyphenol compound or its derivative.
9. The method according to claim 7 , wherein the filter comprises 0.01 g of at least one polyphenol compound or its derivative.
10. The method according to claim 7 , wherein the at least one polyphenol or its derivative is coupled to a polymeric carrier or is in a microcapsule matrix or is added to the fibers of a filter.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2006/044704 WO2008060286A1 (en) | 2006-11-17 | 2006-11-17 | A cigarette filter containing rosemary extract and a method of reducing dna damage caused by harmful agents in cigarette smoke by use of said filter |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20110155157A1 true US20110155157A1 (en) | 2011-06-30 |
Family
ID=39401968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US12/515,040 Abandoned US20110155157A1 (en) | 2006-11-17 | 2006-11-17 | Cigarette filter containing rosemary extract and a method of reducing dna damage caused by harmful agents in cigarette smoke by use of said filter |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20110155157A1 (en) |
| EP (1) | EP2094120A4 (en) |
| JP (1) | JP2010509913A (en) |
| KR (2) | KR20090096444A (en) |
| CN (1) | CN101641023A (en) |
| AU (1) | AU2006350735A1 (en) |
| BR (1) | BRPI0622154A2 (en) |
| CA (1) | CA2668939A1 (en) |
| EA (1) | EA015759B1 (en) |
| NO (1) | NO20091844L (en) |
| WO (1) | WO2008060286A1 (en) |
| ZA (1) | ZA200903381B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017155739A1 (en) * | 2016-03-07 | 2017-09-14 | R.J. Reynolds Tobacco Company | Rosemary in a tobacco blend |
| CN113029710A (en) * | 2021-03-15 | 2021-06-25 | 中国烟草总公司郑州烟草研究院 | Method for extracting whole smoke of heated cigarette for in vitro toxicity test |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012136317A1 (en) * | 2011-04-04 | 2012-10-11 | Cognis Ip Management Gmbh | Rosmarinic acid for smoker dehabituation |
| CN110066863B (en) * | 2019-05-22 | 2023-01-31 | 山西医科大学 | Identification method of BPDE addition gene |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999033365A1 (en) * | 1997-12-24 | 1999-07-08 | Biosynthec | Use of polyphenol compounds or their derivatives as scavengers of free radicals in cigarette filters |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2564296A1 (en) * | 1984-05-16 | 1985-11-22 | Grenet Edouard | Cigarette filter |
| JPH02127194U (en) * | 1989-03-29 | 1990-10-19 | ||
| ATE184789T1 (en) * | 1990-10-06 | 1999-10-15 | Nestle Sa | USE OF CARNOSOLIC ACID FOR ITS ANTICARCINOGENIC AND ANTIVIRAL PROPERTIES |
| JPH07155161A (en) * | 1992-12-26 | 1995-06-20 | Setsuo Kuroki | Complex cigarette |
| CN1073387C (en) * | 1995-09-13 | 2001-10-24 | 北京卷烟厂 | Low free radical and low toxicity cigarette and its prodn. method |
| CN1103197C (en) * | 2000-10-16 | 2003-03-19 | 北京倍和德营养制品科技发展有限公司 | Filter tip capable of eliminating free radical in cigarette fume and its making process |
| US20090028898A1 (en) * | 2005-03-14 | 2009-01-29 | Xixian Qiu | Instant Additive Solution for the Filter of Cigarette, Its Production Method and Use |
-
2006
- 2006-11-17 EA EA200970484A patent/EA015759B1/en not_active IP Right Cessation
- 2006-11-17 CN CN200680056513A patent/CN101641023A/en active Pending
- 2006-11-17 CA CA002668939A patent/CA2668939A1/en not_active Abandoned
- 2006-11-17 JP JP2009537128A patent/JP2010509913A/en active Pending
- 2006-11-17 KR KR1020097011628A patent/KR20090096444A/en not_active Ceased
- 2006-11-17 KR KR1020137024208A patent/KR20130103834A/en not_active Ceased
- 2006-11-17 US US12/515,040 patent/US20110155157A1/en not_active Abandoned
- 2006-11-17 WO PCT/US2006/044704 patent/WO2008060286A1/en not_active Ceased
- 2006-11-17 AU AU2006350735A patent/AU2006350735A1/en not_active Abandoned
- 2006-11-17 EP EP06849893A patent/EP2094120A4/en not_active Withdrawn
- 2006-11-17 BR BRPI0622154-8A patent/BRPI0622154A2/en not_active IP Right Cessation
-
2009
- 2009-05-11 NO NO20091844A patent/NO20091844L/en not_active Application Discontinuation
- 2009-05-15 ZA ZA2009/03381A patent/ZA200903381B/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999033365A1 (en) * | 1997-12-24 | 1999-07-08 | Biosynthec | Use of polyphenol compounds or their derivatives as scavengers of free radicals in cigarette filters |
| US20060213533A1 (en) * | 1997-12-24 | 2006-09-28 | Imam Emami | Use of polyphenol compounds or derivatives thereof as free-radical scavengers in cigarette filters |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017155739A1 (en) * | 2016-03-07 | 2017-09-14 | R.J. Reynolds Tobacco Company | Rosemary in a tobacco blend |
| US10226066B2 (en) | 2016-03-07 | 2019-03-12 | R.J. Reynolds Tobacco Company | Rosemary in a tobacco blend |
| CN113029710A (en) * | 2021-03-15 | 2021-06-25 | 中国烟草总公司郑州烟草研究院 | Method for extracting whole smoke of heated cigarette for in vitro toxicity test |
Also Published As
| Publication number | Publication date |
|---|---|
| NO20091844L (en) | 2009-07-22 |
| JP2010509913A (en) | 2010-04-02 |
| BRPI0622154A2 (en) | 2011-12-27 |
| KR20090096444A (en) | 2009-09-10 |
| ZA200903381B (en) | 2014-10-29 |
| EP2094120A4 (en) | 2012-12-12 |
| EA015759B1 (en) | 2011-12-30 |
| CA2668939A1 (en) | 2008-05-22 |
| EP2094120A1 (en) | 2009-09-02 |
| EA200970484A1 (en) | 2009-10-30 |
| CN101641023A (en) | 2010-02-03 |
| KR20130103834A (en) | 2013-09-24 |
| WO2008060286A1 (en) | 2008-05-22 |
| AU2006350735A1 (en) | 2008-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Alexandrov et al. | DNA damage by benzo (a) pyrene in human cells is increased by cigarette smoke and decreased by a filter containing rosemary extract, which lowers free radicals | |
| Leanderson et al. | Cigarette smoke-induced DNA-damage: role of hydroquinone and catechol in the formation of the oxidative DNA-adduct, 8-hydroxydeoxyguanosine | |
| Staretz et al. | Comparative metabolism of the tobacco-related carcinogens benzo [a] pyrene, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol, and N′-nitrosonornicotine in human hepatic microsomes | |
| NAKAYAMA et al. | Generation of hydrogen peroxide and superoxide anion radical from cigarette smoke | |
| Stevens et al. | Acrolein: sources, metabolism, and biomolecular interactions relevant to human health and disease | |
| Zhou et al. | Role of CYP2A5 in the bioactivation of the lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in mice | |
| Truman et al. | Monoamine oxidase inhibitory activity in tobacco particulate matter: Are harman and norharman the only physiologically relevant inhibitors? | |
| Pouyfung et al. | Mechanism-based inactivation of cytochrome P450 2A6 and 2A13 by Rhinacanthus nasutus constituents | |
| Staretz et al. | Effects of long term dietary phenethyl isothiocyanate on the microsomal metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol in F344 rats. | |
| Sticha et al. | Effects of benzyl isothiocyanate and phenethyl isothiocyanate on DNA adduct formation by a mixture of benzo [a] pyrene and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in A/J mouse lung | |
| Hoffmann et al. | Tobacco smoke as a respiratory carcinogen | |
| US20110155157A1 (en) | Cigarette filter containing rosemary extract and a method of reducing dna damage caused by harmful agents in cigarette smoke by use of said filter | |
| Hoffmann et al. | Tobacco consumption and lung cancer | |
| Hong et al. | Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), a tobacco-specific carcinogen, by rabbit nasal microsomes and cytochrome P450s NMa and NMb | |
| Yoo et al. | Mechanism-based inactivation of cytochrome P450 2A6 by decursinol angelate isolated from Angelica gigas | |
| Smith et al. | A difference between two strains of rats in their liver non-haem iron content and in their response to the porphyrogenic effect of hexachlorobenzene | |
| Nachiappan et al. | Lipid peroxidation and ethanol-related tumor promotion in Fischer-344 rats treated with tobacco-specific nitrosamines | |
| Prokopczyk et al. | Supercritical fluid extraction in the determination of tobacco-specific N-nitrosamines in smokeless tobacco | |
| AU2013216646A1 (en) | A Cigarette Filter Containing Rosemary Extract and a Method of Reducing DNA Damage Caused by Harmful Agents in Cigarette Smoke by Use of Said Filter | |
| JP2013150619A (en) | Tobacco filter including extract of rosemary and method for reducing dna damage caused by harmful material included in tobacco smoke by using the filter | |
| Smoke | DNA Damage by Benzo (a) pyrene in Human Cells Is Increased | |
| HK1137628A (en) | A cigarette filter containing rosemary extract and a method of reducing dna damage caused by harmful agents in cigarette smoke by use of said filter | |
| HK1184648A (en) | A cigarette filter containing rosemary extract and a method of reducing dna damage caused by harmful agents in cigarette smoke by use of said filter | |
| CN103110188A (en) | Cigarette filter tip containing rosemary extractive and method for reducing deoxyribonucleic acid (DNA) damage caused by hazardous substances in smog through using cigarette filter tip | |
| Marcotte et al. | Induction of aryl hydrocarbon hydroxylase in rat lung by marijuana smoke |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |